Pharmaxis Completes Phase 3 Trial Of Bronchitol
The double blind, placebo controlled, randomised study comparing 400mg of Bronchitol twice a day to control included 305 participants, and was conducted across 53 sites in 7 countries.
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.